We love to hear from our listeners. Send us a message. On this week's episode, Joel Latham, President and CEO at Incannex Healthcare, talks about developing cannabinoid and psychedelic combination therapies for conditions as diverse as sleep apnea, rheumatoid arthritis, and generalized anxiety disorder. Joel walks through his funding strategy for the publicly-traded company, his desire to lead in a new category of medicine, and what comes next. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions :
[email protected] Find Ben Comer on LinkedIn : https://www.linkedin.com/in/bencomer/
